HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

PD 198306

structure in first source

Also Known As:

PD198306

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Fluorobenzenes: 14
        PD 198306: 3
  - Halogenated Hydrocarbons: 42
    - Fluorinated Hydrocarbons: 4
      - Fluorobenzenes: 14
        PD 198306: 3

Experts

1.	Brunet, Julie: 1 article (06/2003)
2.	Fernandes, Julio C: 1 article (06/2003)
3.	Flory, Craig: 1 article (06/2003)
4.	Martel-Pelletier, Johanne: 1 article (06/2003)
5.	Moldovan, Florina: 1 article (06/2003)
6.	Pelletier, Jean-Pierre: 1 article (06/2003)
7.	Schrier, Denis: 1 article (06/2003)
8.	Bramwell, S: 1 article (03/2003)
9.	Ciruela, A: 1 article (03/2003)
10.	Dixon, A K: 1 article (03/2003)

Related Diseases

1.	Osteoarthritis 06/01/2003 - "The primary aim of this study was to investigate, using an experimental rabbit model of osteoarthritis (OA), the effect of a selective mitogen-activated protein kinase kinase 1/2 (MEK-1/2) inhibitor, PD 198306, on the development of structural changes. "
2.	Neuralgia (Stump Neuralgia) 03/01/2003 - "(4) The antihyperalgesic effects of PD 198306, in both the streptozocin and CCI models of neuropathic pain, correlated with a reduction in the elevated levels of active ERK1 and 2 in lumbar spinal cord. " 03/01/2003 - "(3) Intrathecal administration of the selective MAPK/ERK-kinase (MEK) inhibitor PD 198306 dose-dependently (1-30 micro g) blocked static allodynia in both the streptozocin and the chronic constriction injury (CCI) models of neuropathic pain. "
3.	Hyperalgesia 03/01/2003 - "(5) Intraplantar administration of PD 198306 had no effect in either model of hyperalgesia, indicating that changes in the activation of ERKs and the effect of MEK inhibition are localized to the central nervous system. " 03/01/2003 - "(3) Intrathecal administration of the selective MAPK/ERK-kinase (MEK) inhibitor PD 198306 dose-dependently (1-30 micro g) blocked static allodynia in both the streptozocin and the chronic constriction injury (CCI) models of neuropathic pain. "
4.	Hepatocellular Carcinoma (Hepatoma) 01/01/2023 - "Small-molecule High-throughput Screening Identifies an MEK Inhibitor PD198306 that Enhances Sorafenib Efficacy via MCL-1 and BIM in Hepatocellular Carcinoma Cells."

Related Drugs and Biologics

1.	Mitogen-Activated Protein Kinase Kinases (MEKs)
2.	MAP Kinase Kinase 1
3.	Streptozocin (Streptozotocin)
4.	Sorafenib (BAY 43-9006)